Cyclo Program Steering Committee News Today

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol Cyclo for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

October 18, 2022

18.10.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ... Seite 1

Caroline Hastings Company Phase Trappsol Cyclo Program Steering Committee Society For Inherited Metabolic Disorders Cyclo Therapeutics Inc Global Principal Investigator For The Company

Source: wallstreet-online.de

JTC Team, LLC: JTC Team to Host Virtual Investor Niemann-Pick Disease Type C Spotlight Event Featuring Cyclo Therapeutics

May 12, 2022

- Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday

Navigation

Cyclo Program Steering Committee News Today

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol Cyclo for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

JTC Team, LLC: JTC Team to Host Virtual Investor Niemann-Pick Disease Type C Spotlight Event Featuring Cyclo Therapeutics

Explore More Categories